Table 2.
Characteristics | HR Injurious falls (95% CI) | P | P | |
---|---|---|---|---|
Gender | ||||
Male | 0.93 (0.55, 1.56) | 0.77 | ||
Female | ref | |||
Age(continuous variable)† | *1.04 (1.01, 1.08) | 0.02 | ||
Falls history | 0.97 (0.48, 1.95) | 0.93 | ||
Visual impairment | 0.86 (0.45, 1.63) | 0.64 | ||
Urinary incontinence | 1.16 (0.69, 1.94) | 0.58 | ||
Parkinson's disease | 0.96 (0.17, 5.50) | 0.96 | ||
Arthritis and other joint diseases | 1.42 (0.81, 2.51) | 0.22 | ||
Depression | 1.95 (0.88, 4.32) | 0.10 | ||
Cardiovascular diseases | 1.34 (0.73, 2.44) | 0.35 | ||
Drug use | Use/no use (95% CI) | Dose–response‡ (95% CI) | ||
Antipsychotics | *1.86 (1.24, 2.78) | 0.00 | 2.21 (0.89, 5.48) | 0.09 |
Anxiolytics | 1.28 (0.78, 2.10) | 0.33 | 1.40 (0.85, 2.33) | 0.19 |
Hypnotics or sedatives | *2.10 (1.19, 3.68) | 0.01 | *2.79 (1.13, 6.91) | 0.03 |
Antidepressants | *2.77 (1.68, 4.57) | 0.00 | *2.96 (1.94, 4.53) | 0.00 |
Tricyclic antidepressants | 1.35 (0.19, 9.65) | 0.77 | 0.23 (0.00, 70.38) | 0.62 |
Selective serotonin re-uptake inhibitors | *2.74 (1.63, 4.62) | 0.00 | *3.00 (1.95, 4.62) | 0.00 |
Other antidepressants | 1.35 (0.39, 4.73) | 0.64 | 1.10 (0.49, 2.49) | 0.81 |
Antihypertensives | 1.39 (0.79, 2.47) | 0.26 | 1.15 (0.91, 1.46) | 0.25 |
Anti-arrythmics | 1.22 (0.59, 2.55) | 0.59 | 1.23 (0.51, 2.98) | 0.65 |
Nitrates and other vasodilators | 0.84 (0.22, 3.22) | 0.80 | 1.31 (0.54, 3.15) | 0.55 |
Digoxin | 0.87 (0.21, 3.58) | 0.84 | 0.77 (0.02, 28.58) | 0.89 |
β-adrenoceptor blocker eye drops | 1.68 (0.23, 12.30) | 0.61 | 1.17 (0.03, 39.71) | 0.93 |
Analgesics | 1.45 (0.48, 4.36) | 0.50 | 1.17 (0.96, 1.43) | 0.11 |
Antihistamines | 0.63 (0.19, 2.12) | 0.46 | 0.91 (0.43, 1.92) | 0.80 |
Drugs used in diabetes | 0.95 (0.34, 2.65) | 0.92 | 1.00 (0.56, 1.78) | 1.00 |
CI, confidence interval; HR, hazard ratio. All estimates are adjusted for gender and age.
Significant parameters.
HR per year.
HR for increase with 1 DDD.